Treatment of Erysipelas in Penicillin-Allergic Patients

First-Line Alternative: Clindamycin

The American Heart Association recommends clindamycin as the most strongly recommended alternative for penicillin-allergic patients with erysipelas, given its excellent streptococcal coverage and low resistance rates (approximately 1% among Group A Streptococcus in the United States) 3
Clindamycin dosing is 300-450 mg orally three times daily for mild-to-moderate cases, or 600 mg intravenously every 8 hours for severe cases requiring hospitalization 2

The Infectious Diseases Society of America suggests macrolides (erythromycin or clarithromycin) are reasonable alternatives for penicillin-allergic patients, though resistance rates have increased to 5-8% in most areas of the United States 4
Erythromycin dosing is 250-500 mg orally four times daily for 10 days 1

The Centers for Disease Control and Prevention recommends doxycycline 100 mg orally twice daily for 7-10 days as an effective alternative for penicillin-allergic patients, particularly those with severe or immediate-type hypersensitivity reactions 1
Doxycycline provides good streptococcal coverage and is well-tolerated with better compliance than tetracycline due to twice-daily dosing 5

The American College of Cardiology recommends intravenous vancomycin (30 mg/kg/day in 2 divided doses) as an effective alternative with excellent streptococcal coverage for severe penicillin allergy with hospitalized patients 2

The American Academy of Allergy, Asthma, and Immunology suggests first-generation cephalosporins (cephalexin, cefadroxil) can be used in patients with non-immediate penicillin allergy, but should be avoided in those with anaphylactic-type reactions due to 5-10% cross-reactivity 1

The American College of Physicians recommends elevation of the affected limb to promote drainage of edema and inflammatory mediators 2
Treatment of the portal of entry (interdigital tinea pedis, eczema, trauma sites) is crucial to prevent recurrence, as suggested by the Infectious Diseases Society of America 2

The American Heart Association advises against using sulfonamides, trimethoprim-sulfamethoxazole, or tetracyclines as monotherapy, as they have poor efficacy against Group A Streptococcus and high resistance rates 4
The Centers for Disease Control and Prevention recommends avoiding empiric MRSA coverage unless there are specific risk factors or failure of initial therapy, as erysipelas is primarily a streptococcal infection 1
Blood cultures are rarely positive (<5% of cases) and are not routinely necessary for typical erysipelas presentations, according to the Infectious Diseases Society of America 1